Immunic (NASDAQ:IMUX) Upgraded to Hold Rating by StockNews.com

Immunic (NASDAQ:IMUX) received an upgrade from StockNews.com, moving from a "sell" rating to a "hold" rating according to a report published on Wednesday.

In addition to StockNews.com's assessment, other analysts have also provided their evaluations of Immunic. HC Wainwright maintained a "buy" rating on the company's shares, setting a target price of $10.00 in a report dated February 21. Similarly, D. Boral Capital reiterated a "buy" rating with a price target of $17.00 in a note released on February 26. Overall, among the analysts covering Immunic, one has rated it with a hold, six have issued buy ratings, and two have assigned a strong buy rating. MarketBeat.com indicates that the consensus rating for Immunic is "Buy" with an average price target of $12.67.

Immunic Stock Performance

On Wednesday, shares of NASDAQ:IMUX experienced a slight increase, rising by $0.06 to reach $1.16. The trading volume for the day was 482,325 shares, which is below its average volume of 943,320. Over the past year, Immunic's stock hit a low of $0.92 and a high of $2.11. Currently, the company has a 50-day moving average price of $1.05 and a 200-day moving average price of $1.23. The market capitalization for Immunic is approximately $104.49 million, with a PE ratio of -0.94 and a beta value of 1.89.

Institutional Inflows and Outflows

Recent changes in holdings by institutional investors also reflect growing interest in Immunic. Invesco Ltd. acquired a new position in Immunic during the fourth quarter, valued at $37,000. Virtu Financial LLC secured a stake worth $50,000 in the third quarter. Furthermore, HB Wealth Management LLC purchased approximately $81,000 worth of shares in the fourth quarter, while Barclays PLC acquired a new position valuing around $84,000 during the same period. Additionally, Jane Street Group LLC increased its stake in Immunic by 121.4% in the third quarter, now owning 70,299 shares worth $116,000 after purchasing an extra 38,553 shares. Overall, institutional investors and hedge funds hold about 51.82% of Immunic's stock.

About Immunic

Immunic, Inc. is a biotechnology company focused on developing selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. Its leading program, IMU-838, is currently in Phase 3 clinical trials targeting treatment for multiple sclerosis, including both relapsing and progressive types, along with moderate-to-severe ulcerative colitis.

Stocks, Healthcare, Biotechnology